Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.74 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827013 | 1.00 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826398 | 1.00 | SLC16A1 (1.00) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826943 | 0.95 | SLC16A1 (0.90) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826941 | 0.95 | SLC16A1 (0.90) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826257 | 0.91 | SLC16A1 (0.84) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826254 | 0.91 | SLC16A1 (0.84) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3831568 | 0.91 | SLC16A1 (0.83) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3826966 | 0.91 | SLC16A1 (0.83) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL5263359 | 0.90 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL5263356 | 0.90 | SLC16A1 (0.82) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | claimed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | claimed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | claimed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | claimed |
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885CYP2C9 89/4885CYP3A4 93/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.